Antibody-based therapeutics are advancing in clinical development at a rapid rate and being approved in record numbers.
To keep our members up to date on recent events, we compile relevant information from news releases and other sources, and send this “Antibody News You Should Know” to our members via email twice per month. We include news about clinical studies that started recently (first-in-human, Phase 2 or Phase 3), the submission of marketing applications, and marketing approvals, as well as other news such as licensing deals and regulatory agency designations (e.g., Orphan Drug) that were granted.
As a service to the community, The Antibody Society offers access to past “Antibody News You Should Know” emails compiled into PDFs. The PDFs include links to the original source and can be searched by keywords (e.g., bispecific, antibody-drug conjugate).
Click here for Antibody News from April 15, 2019 to December 31, 2019.
During 2020, “Antibody News You Should Know” compiled into PDFs will be posted on a quarterly basis.
If you are not already a Society member, please register to receive Antibody News as emails delivered twice per month.
